Arrowhead Application OKd for Familial Chylomicronemia Syndrome Therapy

 - The New Drug Application is based on positive results from the Phase 3 PALISADE study

- People living with familial chylomicronemia syndrome have extremely high triglyceride levels and a substantially higher risk of developing acute pancreatitis and associated long-term complications, including poor quality of life

https://www.businesswire.com/news/home/20250117349461/en